Olaparib Parp Inhibitors Inherited Ovarian Cancer Results

(Ovarian Cancer Parp Inhibitors Research) The experimental cancer drug olaparib, a drug in the promising class of drugs known as PARP Inhibitors,  produced promising results in patients with ovarian cancer linked to an inherited BRCA1 or BRCA2 gene mutation. The trial results were published in the Journal of Clinical Oncology on April 19th, 2010. Scientists at The Institute …

Olaparib Parp Inhibitors Inherited Ovarian Cancer ResultsRead More »

AstraZeneca’s Foray into Parp Inhibitors Started in 2006

AstraZeneca stands to benefit greatly from the successful studies, to date, on the use of Parp Inhibitors in the treatment of cancer. The targeted treatment received mass publicity in June 2009 when a study came out showed great promise and results. So how did AstraZeneca become involved with parp inhibitors? In 2006, AstraZeneca acquired a …

AstraZeneca’s Foray into Parp Inhibitors Started in 2006Read More »